What Happened
Panama’s Regional Center for Vaccine and Biopharmaceutical Innovation is advancing toward full operation at its home in Clayton, where a historic 1941 building now houses one of the country’s most ambitious scientific projects. The center occupies 1,400 square meters in Building 219, a structure that once served as the Clayton commissary before later becoming a training facility and then the site of Indicasat-AIP.
The center was inaugurated in September 2025 and is expected to begin operating in June. According to its director, Paulina Franceschi, the facility is already more than 80% equipped and is now focused on finalizing laboratories, validating procedures and completing biosafety systems.
The project is designed to position Panama as a regional biotechnology reference, with a focus on next-generation vaccines and biopharmaceuticals that can help address future health threats.
Strategic Equipment and Research Capacity
Several specialized pieces of equipment are still being incorporated to complete the center’s scientific platform. Among the most important is a cell sorter cytometer, which can isolate highly purified biological samples and identify cell populations useful in antibody development and biopharmaceutical research.
Another major addition is an mRNA platform, a technology that gained global prominence during the COVID-19 pandemic. It allows the design, production and evaluation of vaccine candidates based on messenger RNA and is described as the only system of its kind in Central America and the Caribbean.
The center is also preparing to work with humanized monoclonal antibodies, a class of advanced therapies used in cancer, autoimmune diseases and other complex conditions. Together, these tools are intended to shorten research timelines and speed the path from laboratory work to practical biomedical solutions.
Why It Matters for Panama and the Region
The project reflects a broader push for health sovereignty in Panama, Central America and the Caribbean. The pandemic exposed how dependent many countries remain on foreign vaccine supply chains and fragile medical logistics. By developing local research capacity, Panama aims to strengthen its ability to respond to future outbreaks and build more durable scientific infrastructure.
The research agenda includes respiratory viruses, influenza and dengue, along with neglected tropical diseases such as leishmaniasis, trypanosomiasis and toxoplasmosis. These diseases remain important not only for public health but also for agriculture and food security, especially as climate change expands the range of disease-carrying vectors.
The center currently has six researchers working in virology, parasitology, epidemiology and biotechnology. Scientists trained abroad have also returned through reintegration programs, adding international experience to the team. The project is supported by international advisers, including María Elena Bottazzi and Panamanian scientist Abel De La Rosa.
Funding and Long-Term Vision
The first phase of the center required an investment of about $10 million for design, construction, equipment, laboratories and furniture. To finish the equipment package, National Secretary of Science, Technology and Innovation Eduardo Ortega Barría requested a $1 million budget transfer before the National Assembly’s Budget Committee.
Looking ahead, the project’s second phase could require an additional $70 million to $100 million if Panama moves toward local vaccine filling, labeling and possible manufacturing. That would deepen the country’s role in the regional biomedical supply chain and reduce dependence on imports for critical health products.
The center is linked to a network that includes Ciudad del Saber, Indicasat AIP, the Gorgas Memorial Institute, the University of Panama, Baylor College of Medicine, Texas Children’s Hospital and the Embassy of South Korea. A cooperation agreement with Brazil’s Fiocruz was also signed to strengthen scientific collaboration in immunobiologicals and expand Panama’s role in vaccine research and training.